Agile Therapeutics Inc ROCE
Was ist das ROCE von Agile Therapeutics Inc?
ROCE von Agile Therapeutics Inc ist 124.01%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Agile Therapeutics Inc
Was macht Agile Therapeutics Inc?
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Unternehmen mit roce ähnlich Agile Therapeutics Inc
- Gridsum Inc hat ROCE von 120.20%
- Troy Resources hat ROCE von 120.84%
- Youdao hat ROCE von 121.94%
- Redhill Biopharma hat ROCE von 123.00%
- Mountain Crest Acquisition Corp hat ROCE von 123.33%
- Guardian Exploration hat ROCE von 123.73%
- Agile Therapeutics Inc hat ROCE von 124.01%
- Amarillo Biosciences hat ROCE von 124.14%
- Plus Therapeutics hat ROCE von 125.08%
- Trend Innovations hat ROCE von 125.59%
- Quest Water Global hat ROCE von 129.00%
- Kiadis Pharma N.V hat ROCE von 129.18%
- Plymouth Realty Capital hat ROCE von 130.50%